Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Brain Behav. 2023 May;13(5):e2962. doi: 10.1002/brb3.2962. Epub 2023 Mar 28.
A high residual risk of subsequent stroke suggested that the predictive ability of Stroke Prognosis Instrument-II (SPI-II) and Essen Stroke Risk Score (ESRS) may have changed over the years.
To explore the predictive values of the SPI-II and ESRS for 1-year subsequent stroke risk in a pooled analysis of three consecutive national cohorts in China over 13 years.
In the China National Stroke Registries (CNSRs), 10.7% (5297/50,374) of the patients had a subsequent stroke within 1 year; area under the curve (AUC) of SPI-II and ESRS was .60 (95% confidence interval [CI]: .59-.61) and .58 (95% CI: .57-.59), respectively. For SPI-II, the AUC was .60 (95% CI: .59-.62) in CNSR-I, .60 (95% CI: .59-.62) in CNSR-II, and .58 (95% CI: .56-.59) in CNSR-III over the past 13 years. The declining trend was also found in ESRS scale (CNSR-I: .60 [95% CI: .59-.61]; CNSR-II: .60 [95% CI: .59-.62]; and CNSR-III: .56 [95% CI: .55-.58]).
The predictive power of the traditional risk scores SPI-II and ESRS was limited and gradually decreased over the past 13 years, thus the scales may not be useful for current clinical practice. Further derivation of risk scales with additional imaging features and biomarkers may be warranted.
较高的后续卒中残余风险表明,卒中预后工具-II(SPI-II)和 Essen 卒中风险评分(ESRS)的预测能力可能随时间发生了变化。
通过对中国三个连续的国家队列研究进行 13 年的汇总分析,探讨 SPI-II 和 ESRS 对 1 年内卒中复发风险的预测价值。
在中国国家卒中登记研究(CNSR)中,10.7%(5297/50374)的患者在 1 年内发生了后续卒中;SPI-II 和 ESRS 的曲线下面积(AUC)分别为 0.60(95%置信区间[CI]:0.59-0.61)和 0.58(95%CI:0.57-0.59)。对于 SPI-II,CNSR-I 的 AUC 为 0.60(95%CI:0.59-0.62),CNSR-II 为 0.60(95%CI:0.59-0.62),CNSR-III 为 0.58(95%CI:0.56-0.59),在过去 13 年中呈下降趋势。ESRS 评分也呈现出下降趋势(CNSR-I:0.60 [95%CI:0.59-0.61];CNSR-II:0.60 [95%CI:0.59-0.62];CNSR-III:0.56 [95%CI:0.55-0.58])。
传统风险评分 SPI-II 和 ESRS 的预测能力有限,且在过去 13 年中逐渐下降,因此这些评分可能不适用于当前的临床实践。可能需要进一步开发具有附加影像学特征和生物标志物的风险评分。